Page 365 - Binder2

In preclinical studies, oral administration of FVIII-
expressing lettuce prevented the development of anti-FVIII
antibodies and preserved therapeutic efficacy in mouse
models—suggesting a viable pathway to prevent immune
rejection in human patients.

Enter Zea.

With its proprietary AI-driven growth and expression
platform, Zea partnered with Daniell to take this innovation
from lab bench to scalable therapy. Zea’s system ensures:

● Controlled protein expression and batch
reproducibility
● Pharmaceutical-grade consistency in freeze-dried
capsules
● Modular, decentralized manufacturing fit for global
use

The result? A needle-free immune tolerization therapy
for one of the most immunogenic drugs in the world. A
treatment that doesn’t just work—it keeps working.

The Broader Implication: Disruption by Design

These case studies underscore the core threat edible
biologics pose to legacy pharma:

● They bypass cold chain.
● They empower local production.
● They eliminate the need for sterile injectables.
● And most dangerously—they induce immune
tolerance, making biologics more durable and less
replaceable.

363